Reviewing Cassava Sciences (NASDAQ:FLNA) and Shuttle Pharmaceuticals (NASDAQ:SHPH)

Cassava Sciences (NASDAQ:FLNA) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cassava Sciences and Shuttle Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1	0	1	0	2.00
Shuttle Pharmaceuticals	1	0	0	0	1.00

Cassava Sciences presently has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Shuttle Pharmaceuticals.

Risk and Volatility

Cassava Sciences has a beta of -0.71, meaning that its stock price is 171% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Profitability

This table compares Cassava Sciences and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Valuation & Earnings

This table compares Cassava Sciences and Shuttle Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97 million	($1.61)	-0.82
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($4.77)	-0.10

Cassava Sciences is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cassava Sciences beats Shuttle Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Cassava Sciences

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.